10-QPeriod: Q2 FY2025

AGILENT TECHNOLOGIES, INC. Quarterly Report for Q2 Ended Apr 30, 2025

Filed June 2, 2025For Securities:A

Summary

Agilent Technologies, Inc. reported net revenue of $1.67 billion for the third quarter of fiscal year 2025, representing a 6% increase year-over-year, with growth driven by its Life Sciences and Diagnostics Markets and Agilent CrossLab segments. For the first six months of fiscal year 2025, net revenue grew 4% to $3.35 billion. Net income for the quarter was $215 million, a decrease from $308 million in the prior year's quarter, impacted by increased restructuring expenses and other costs. The company is navigating a dynamic economic landscape, including inflationary pressures and tariff changes, and is implementing strategies to mitigate these impacts. Despite a decrease in net income for the quarter, driven largely by a significant restructuring charge of $56 million, the company maintained a healthy revenue growth trajectory. Agilent continues to invest in its core segments, particularly Life Sciences and Diagnostics Markets, supported by the BIOVECTRA acquisition. The company is also actively managing its capital structure through share repurchases and dividends, returning value to shareholders while strategically investing in manufacturing capacity expansion.

Financial Highlights

57 data points
Beta

Revenue

$1.67B

51.9% Gross Margin

Net Income

$215.00M

12.9% Net Margin

EPS (Diluted)

$0.75

Total Assets

$12.16B

Cash & Equivalents

$1.49B

Free Cash Flow

$107.00M

Financial Statements
Beta
Revenue$1.67B
Cost of Revenue$802.00M
Gross Profit$866.00M
R&D Expenses$112.00M
SG&A Expenses$454.00M
Operating Expenses$1.37B
Operating Income$300.00M
Interest Expense$29.00M
Net Income$215.00M
EPS (Basic)$0.75
EPS (Diluted)$0.75
Shares Outstanding (Basic)285.00M
Shares Outstanding (Diluted)285.00M

Key Highlights

  • 1Total net revenue for the three months ended April 30, 2025 was $1.67 billion, up 6% year-over-year.
  • 2Net income for the three months ended April 30, 2025 was $215 million ($0.75 per diluted share), down from $308 million ($1.05 per diluted share) in the prior year period.
  • 3Operating margin decreased to 18.0% from 23.1% year-over-year, primarily due to higher restructuring expenses and other operating costs.
  • 4Life Sciences and Diagnostics Markets segment revenue grew 8% year-over-year, and Agilent CrossLab segment revenue increased 7%.
  • 5The Applied Markets segment saw a 1% decrease in revenue year-over-year.
  • 6The company recorded $56 million in restructuring and other related costs during the quarter, impacting profitability.
  • 7Agilent continued its share repurchase program, buying back approximately $165 million worth of stock during the quarter.

Frequently Asked Questions

Agilent Technologies reported a 6% increase in net revenue to $1.67 billion for the three months ended April 30, 2025, compared to the same period last year. However, net income decreased to $215 million from $308 million in the prior year's quarter, largely impacted by significant restructuring charges and other operating costs which compressed the operating margin.

The Life Sciences and Diagnostics Markets segment and the Agilent CrossLab segment were the primary drivers of revenue growth, with increases of 8% and 7% respectively. The Applied Markets segment experienced a slight revenue decline of 1% year-over-year.

The company incurred $56 million in restructuring and other related costs during the quarter, significantly impacting profitability and contributing to the year-over-year decline in net income and operating margin. These costs are part of broader restructuring plans aimed at optimizing management structure and reducing expenses.

Agilent continues to actively manage its capital through share repurchases and dividend payments. During the quarter, the company repurchased approximately $165 million of its common stock under its authorized repurchase program and declared a quarterly dividend of $0.248 per share.